2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …

RA Byrne, X Rossello, JJ Coughlan… - … Heart Journal: Acute …, 2024 - academic.oup.com
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Is it time to switch to bivalirudin for ECMO anticoagulation?

A Navaei, V Kostousov, J Teruya - Frontiers in Medicine, 2023 - frontiersin.org
For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant
used for extracorporeal membrane oxygenation (ECMO) support. More recently, however …

An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial

M Natsuaki, H Watanabe, T Morimoto, K Yamamoto… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …

Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management

C Laudani, D Capodanno… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Introduction In patients with acute coronary syndrome (ACS), the ischemic benefit of
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized …

Y Yan, J Guo, X Wang, G Wang, Z Fan, D Yin, Z Wang… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after
primary percutaneous coronary intervention in ST-segment–elevation myocardial infarction …

Bivalirudin in acute coronary syndromes

M Galli, M Bernardi, L Ortega-Paz, R Nerla… - Expert Review of …, 2023 - Taylor & Francis
Introduction Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce
bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) …

Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis

PR Oli, DB Shrestha, J Shtembari… - Coronary Artery …, 2023 - journals.lww.com
Background The use of bivalirudin-based anticoagulation over heparin-based
anticoagulation for coronary percutaneous intervention has been debated for a long time …

A revolution in the management of multidrug-resistant tuberculosis

K Dheda, C Lange - The Lancet, 2022 - thelancet.com
Comment 1824 www. thelancet. com Vol 400 November 26, 2022 considerable toxicity. The
investigators of the STREAM stage 1 trial established that a 9-month injectable-based …

Impact of bivalirudin on ischemia/reperfusion injury in patients with reperfused STEMI assessed by cardiac magnetic resonance

Y Zhang, Z Zou, B Xu, B Chen, H Ge, S Ding, J Pu - Pharmaceuticals, 2024 - mdpi.com
Thrombin is an important ischemia/reperfusion injury (IRI) mediator in patients with ST-
elevation myocardial infarction (STEMI). This study examines the use of bivalirudin, a direct …

Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta …

A Al-Abdouh, M Mhanna, A Jabri, L Madanat… - Cardiovascular …, 2024 - Elsevier
Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …